Quarterly report · Q2
4548.TEDINET S100SALX
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥79.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥77.8bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥71.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥69.8bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.0bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥490m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥268m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥731m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.54 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.93 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.72 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥420m |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 525
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1YTDDuration | -932000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -843000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -709000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -21000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -23000000 | JPY |
| Repayments of sales and instalment back transactions fin cf | Prior1YTDDuration | -85000000 | JPY |
| Repayments of sales and instalment back transactions fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | -0 | JPY |
| Other net fin cf | CurrentYTDDuration | 0 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -1883000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -731000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 1300000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 989000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 1024000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -4811000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 23367000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 25798000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 24391000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 20987000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00970-000PharmaceuticalReportableSegmentsMember | 11692000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00970-000LALReportableSegmentsMember | 5566000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 17258000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 17258000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00970-000PharmaceuticalReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00970-000LALReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00970-000PharmaceuticalReportableSegmentsMember | 11692000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00970-000LALReportableSegmentsMember | 5566000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 17258000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 17258000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00970-000PharmaceuticalReportableSegmentsMember | 1166000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00970-000LALReportableSegmentsMember | 1443000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 2610000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 2610000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00970-000PharmaceuticalReportableSegmentsMember | 13091000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00970-000LALReportableSegmentsMember | 4970000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 18061000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 18061000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00970-000PharmaceuticalReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00970-000LALReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |